Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
Aprea Therapeutics (Nasdaq: APRE) has engaged Philippe Pultar, MD as senior medical advisor to support the development of APR-1051, their potential best-in-class WEE1 inhibitor. Dr. Pultar brings extensive oncology experience, including the development of azenosertib, another WEE1 inhibitor. This aligns with Aprea's commitment to providing top resources for their WEE1 inhibitor program.
The Phase 1 ACESOT-1051 study is ongoing, evaluating APR-1051 in advanced solid tumors with specific gene alterations. Aprea plans to update on this study by year-end 2024. The WEE1 program is part of Aprea's DDR-targeted therapeutics portfolio, aiming to deliver precision medicine solutions.
Dr. Pultar expressed excitement about APR-1051's potential, citing its differentiated profile and compelling pre-clinical data. Aprea's CEO, Oren Gilad, Ph.D., highlighted Dr. Pultar's expertise as valuable for advancing their WEE1 program. Concurrently, Dr. Nadeem Mirza will step down as Chief Medical Officer, effective October 9, 2024.
Aprea Therapeutics (Nasdaq: APRE) ha scelto Philippe Pultar, MD come consulente medico senior per supportare lo sviluppo di APR-1051, il loro potenziale inibitore WEE1 di prima classe. Il Dr. Pultar porta con sé una vasta esperienza in oncologia, compreso lo sviluppo di azenosertib, un altro inibitore WEE1. Questo è in linea con l'impegno di Aprea di fornire risorse di alta qualità per il loro programma di inibitori WEE1.
Lo studio Phase 1 ACESOT-1051 è attualmente in corso, valutando APR-1051 in tumori solidi avanzati con specifiche alterazioni genetiche. Aprea prevede di fornire aggiornamenti su questo studio entro la fine del 2024. Il programma WEE1 fa parte del portafoglio terapeutico mirato DDR di Aprea, con l'obiettivo di offrire soluzioni di medicina di precisione.
Il Dr. Pultar ha espresso entusiasmo riguardo al potenziale di APR-1051, citando il suo profilo differenziato e i dati preclinici convincenti. L'amministratore delegato di Aprea, Oren Gilad, Ph.D., ha sottolineato che l'esperienza del Dr. Pultar è preziosa per far avanzare il loro programma WEE1. Contestualmente, Dr. Nadeem Mirza si dimetterà dalla carica di Chief Medical Officer, con effetto dal 9 ottobre 2024.
Aprea Therapeutics (Nasdaq: APRE) ha contratado a Philippe Pultar, MD como asesor médico senior para apoyar el desarrollo de APR-1051, su potencial inibidor WEE1 de clase mundial. El Dr. Pultar aporta una amplia experiencia en oncología, incluido el desarrollo de azenosertib, otro inibidor WEE1. Esto está alineado con el compromiso de Aprea de proporcionar los mejores recursos para su programa de inibidores WEE1.
El estudio Phase 1 ACESOT-1051 está en curso, evaluando APR-1051 en tumores sólidos avanzados con alteraciones genéticas específicas. Aprea planea actualizar sobre este estudio para finales de 2024. El programa WEE1 es parte del portafolio terapéutico dirigido a DDR de Aprea, que busca ofrecer soluciones de medicina de precisión.
El Dr. Pultar expresó su entusiasmo por el potencial de APR-1051, citando su perfil diferenciado y los convincentes datos preclínicos. El CEO de Aprea, Oren Gilad, Ph.D., destacó que la experiencia del Dr. Pultar es valiosa para avanzar en su programa WEE1. Al mismo tiempo, Dr. Nadeem Mirza renunciará como Director Médico, efectivo el 9 de octubre de 2024.
아프레아 치료제(Aprea Therapeutics) (Nasdaq: APRE)는 Philippe Pultar, MD를 수석 의료 고문으로 영입하여 잠재적인 최고급 WEE1 억제제인 APR-1051 개발을 지원하게 했습니다. Pultar 박사는 다른 WEE1 억제제인 아제노세르티브(azenosertib)의 개발을 포함하여 광범위한 종양학 경험을 가지고 있습니다. 이는 아프레아의 WEE1 억제제 프로그램에 최상의 자원을 제공하려는 약속과 일치합니다.
현재 Phase 1 ACESOT-1051 연구가 진행 중이며, 이는 특정 유전자 변이가 있는 고급 고형 종양에서 APR-1051을 평가하고 있습니다. 아프레아는 2024년 연말까지 이 연구에 대한 업데이트를 계획하고 있습니다. WEE1 프로그램은 아프레아의 DDR 표적 치료제 포트폴리오의 일부로, 정밀 의학 솔루션을 제공하는 것을 목표로 하고 있습니다.
Pultar 박사는 APR-1051의 잠재력에 대한 기대감을 표명하며, 차별화된 프로필과 매력적인 전임상 데이터를 언급했습니다. 아프레아의 CEO인 Oren Gilad, Ph.D.는 Pultar 박사의 전문성이 WEE1 프로그램을 발전시키는 데 귀중하다고 강조했습니다. 동시에 Dr. Nadeem Mirza는 2024년 10월 9일부터 최고 의료 책임자직에서 물러납니다.
Aprea Therapeutics (Nasdaq: APRE) a engagé Philippe Pultar, MD en tant que conseiller médical senior pour soutenir le développement de APR-1051, leur potentiel inhibiteur WEE1 de premier plan. Le Dr Pultar apporte une vaste expérience en oncologie, notamment dans le développement de l'azenocertib, un autre inhibiteur WEE1. Cela s'inscrit dans l'engagement d'Aprea à fournir des ressources de premier ordre pour leur programme d'inhibiteurs WEE1.
La phase 1 de l'étude ACESOT-1051 est en cours, évaluant APR-1051 dans des tumeurs solides avancées présentant des altérations génétiques spécifiques. Aprea prévoit de mettre à jour cette étude d'ici la fin 2024. Le programme WEE1 fait partie du portefeuille de thérapeutiques ciblant les DDR d'Aprea, visant à fournir des solutions de médecine de précision.
Le Dr Pultar a exprimé son enthousiasme quant au potentiel d'APR-1051, citant son profil différencié et ses données précliniques convaincantes. Le PDG d'Aprea, Oren Gilad, Ph.D., a souligné que l'expertise du Dr Pultar est précieuse pour faire avancer leur programme WEE1. Parallèlement, Dr. Nadeem Mirza démissionnera de son poste de directeur médical, à compter du 9 octobre 2024.
Aprea Therapeutics (Nasdaq: APRE) hat Philippe Pultar, MD als senior medizinischen Berater engagiert, um die Entwicklung von APR-1051, ihrem potenziell besten WEE1-Hemmer, zu unterstützen. Dr. Pultar bringt umfassende Onkologie-Erfahrung mit, darunter die Entwicklung von azenosertib, einem anderen WEE1-Hemmer. Dies steht im Einklang mit Apréas Engagement, erstklassige Ressourcen für ihr WEE1-Hemmer-Programm bereitzustellen.
Die laufende Phase 1 ACESOT-1051-Studie bewertet APR-1051 bei fortgeschrittenen soliden Tumoren mit spezifischen genetischen Änderungen. Aprea plant, bis Ende 2024 ein Update zu dieser Studie zu veröffentlichen. Das WEE1-Programm ist Teil von Apréas DDR-zielgerichteter Therapeutika-Portfolio, das darauf abzielt, Lösungen für Präzisionsmedizin zu liefern.
Dr. Pultar äußerte Begeisterung über das Potenzial von APR-1051 und verwies auf dessen differenziertes Profil und überzeugende präklinische Daten. Apréas CEO, Oren Gilad, Ph.D., betonte, dass Dr. Pultars Expertise wertvoll für den Fortschritt ihres WEE1-Programms sei. Gleichzeitig wird Dr. Nadeem Mirza mit Wirkung zum 9. Oktober 2024 als Chief Medical Officer zurücktreten.
- Engagement of Philippe Pultar, MD, an experienced oncology expert, as senior medical advisor
- Ongoing Phase 1 ACESOT-1051 study evaluating APR-1051 in advanced solid tumors
- APR-1051 shows potential to be a best-in-class WEE1 inhibitor
- Aprea's commitment to providing top resources for their WEE1 inhibitor program
- Chief Medical Officer Dr. Nadeem Mirza stepping down, potentially causing leadership transition challenges
Insights
The engagement of Dr. Philippe Pultar as senior medical advisor for Aprea Therapeutics' WEE1 inhibitor program is a strategic move that could significantly impact the company's clinical development efforts. Dr. Pultar's extensive experience with WEE1 inhibitors, particularly his role in developing azenosertib at Zentalis Pharmaceuticals, brings valuable expertise to Aprea's APR-1051 program.
Key points to consider:
- APR-1051 is currently in Phase 1 trials (ACESOT-1051 study) for advanced solid tumors with specific genetic alterations.
- The company aims to provide an update on this study by the end of 2024.
- Aprea is positioning APR-1051 as a potential best-in-class WEE1 inhibitor, which could be a significant differentiator in the competitive oncology market.
- The departure of Dr. Nadeem Mirza as CMO introduces some uncertainty, but the transition period until December 13, 2024, should help mitigate risks.
While this news doesn't immediately impact financials, it strengthens Aprea's development capabilities and could accelerate the progress of APR-1051, potentially leading to value creation in the medium to long term.
DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea’s potential best in class WEE1 inhibitor.
Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stage pharmaceutical companies. Engaging Dr. Pultar aligns with Aprea’s commitment to provide its WEE1 inhibitor program with all the necessary resources, including the best available professional talent and expertise, to succeed. Dr. Pultar was most recently employed at Zentalis Pharmaceuticals where he played a key role in the strategy and execution of the global clinical development of azenosertib, a WEE1 inhibitor.
Patient enrollment is currently ongoing in the Phase 1 ACESOT-1051 study, designed to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of single-agent APR-1051 in advanced solid tumors harboring certain cancer-associated gene alterations. Aprea intends to provide an update on the progress of this clinical study by year end 2024. The WEE1 program is part of Aprea’s portfolio of DDR-targeted therapeutics aimed to deliver precision medicine solutions that ensure the right patients receive the most effective Aprea treatment, with the goals of improving outcomes and reducing treatment resistance.
“WEE1 inhibition is a promising therapeutic approach in oncology and my prior experience has given me a thorough understanding of biomarker driven clinical studies, the development and regulatory landscape as well as the likely attributes for a successful therapeutic,” said Dr. Pultar. “Aprea has a great opportunity to be a leader in this space. I am quite impressed by the progress the team has made advancing APR-1051, which has a differentiated profile, and is supported by compelling pre-clinical data. I am very excited to be associated with this program and I believe APR-1051 has the potential to be best in class. I look forward to working with the talented scientists at Aprea with the goals of advancing its WEE1 program and bringing new treatments to patients battling difficult-to-treat cancers.”
“Dr. Pultar is a highly capable scientific leader with a track record of successfully leading programs through late-stage development and regulatory approval,” said Oren Gilad, Ph.D., President and CEO of Aprea. “Given the recent initiation of our Phase 1 ACESOT-1051 clinical trial evaluating our promising WEE1 inhibitor, APR-1051, we are excited to bring on a high caliber advisor such as Dr. Pultar. Dr. Pultar’s prior experience in managing multiple clinical trials for a WEE1 inhibitor is particularly relevant and we hope to leverage his expertise as we advance our own program and maximize the therapeutic potential of APR-1051. His addition to the team is part of our broader strategy to bring in exceptional talent with the experience and skills to successfully advance our programs.”
Dr. Nadeem Mirza will be stepping down as Chief Medical Officer effective as of October 9, 2024, to pursue other professional endeavors but will remain with the Company through a date not later than December 13, 2024, to ensure a smooth leadership transition.
About Philippe Pultar, MD
Dr. Pultar brings over 17 years of extensive experience in early and late-stage clinical development. From 2020 to 2023 he was Vice President, Clinical Development at Zentalis Pharmaceuticals where he was responsible for the strategy and execution of the global clinical development of azenosertib, working closely with co-development partners GSK, Pfizer, and Zentera for China. He initiated seven Phase 1 and Phase 2 trials with azenosertib as single agent and in combination with chemotherapy and targeted agents across multiple indications. Prior to Zentalis, he spent seven years at Novartis Oncology (2013 to 2020), including as Senior Clinical Development Medical Director. He was appointed Medical Lead in rare diseases and was assigned to New Drug Application (NDA) activities for Isturisa® (osilodrostat). He led the writing and review of key EU and US NDA documents for Isturisa®, resulting in its approval with broad indication in Cushing’s syndrome with limited post-approval commitments. He was also Medical Lead for Phase 2, 3 and 4 trials on Isturisa®, Signifor® (pasireotide) and Odomzo® (sonidegib). Prior to Novartis he was employed in senior clinical development roles at Agennix AG (2011 to 2013) and ImClone Systems (2007 to 2011). Earlier in his career, he held positions at GPC Biotech, ALTANA Pharma, REDEON and MEDICERCLE.
Dr. Pultar earned his medical thesis from Université de Médecine de Poitiers, France and practiced as a physician for several years. His foundational education includes Medical Studies and Residency at Université de Médecine de Poitiers, providing him with a solid academic background to complement his extensive practical experience in clinical development.
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at https://aprea.com/.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
FAQ
What is the purpose of Aprea Therapeutics engaging Philippe Pultar, MD?
What is the current status of Aprea's APR-1051 clinical trial?
When will Aprea Therapeutics (APRE) provide an update on the ACESOT-1051 clinical study?